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BRIEF DEFINITIVE REPORT
        Several lines of evidence demonstrate that the 
immune system protects the host against tumor 
development. CTL and NK cells are major play-
ers in cell-mediated immunity to tumors (  1, 2  ). 
Tumor recognition by and activation of CTL 
and NK cells are mediated by antigen receptors 
and a variety of adhesion and costimulatory mol-
ecules including CD2, LFA-1 (leukocyte func-
tion-associated antigen-1; CD11a/CD18), 
CD27, 2B4, CD28, ICOS (inducible costimula-
tor), NKG2D, TRAIL (TNF-related apoptosis-
inducing ligand), and others (  2, 3  ). Interactions of 
these cell surface receptors with their respective 
ligands expressed on tumors induce cytotoxic ac-
tivity of CTL and NK cells against tumors (  4  ). 
  DNAM-1 (CD226) is a member of the im-
munoglobulin superfamily and is expressed on 
the majority of NK cells, T cells, monocytes, 
and platelets (  5  –  7  ). DNAM-1 constitutively as-
sociates with LFA-1 on NK cells (  8  ). Ligation 
of LFA-1 with antibodies causes Fyn-depen-
dent phosphorylation of tyrosine residues in 
the cytoplasmic domain of DNAM-1, which 
are necessary for DNAM-1  –  dependent NK cell 
functions ( 8  ). DNAM-1 also associates with LFA-
1 in activated T cells, for which the protein ki-
nase C  –  induced serine phosphorylation in the 
cytoplasmic domain of DNAM-1 is responsible 
(  8  ), and is involved in an LFA-1  –  mediated 
costimulatory signal for naive T cell diff  erenti-
ation and proliferation (  9  ). The poliovirus re-
ceptor (PVR) CD155 and its family member 
CD112 (PRR-2 [PVR-related family 2], also 
called nectin-2) are ligands for human and 
mouse DNAM-1 (  10  –  12  ). Interactions between 
DNAM-1 on NK cells and T cells and its li-
gands CD112 and CD155 on tumor cells aug-
ment cell-mediated cytotoxicity and cytokine 
production (  10, 11  ). Although human CD112 
and CD155 are broadly distributed on epithe-
lial and endothelial cells in many tissues (  13, 14  ), 
they are overexpressed on certain tumors, both 
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  Since the identifi  cation of ligands for human and mouse DNAM-1, emerging evidence has 
suggested that DNAM-1 plays an important role in the T cell  –   and natural killer (NK) cell  –
  mediated recognition and lysis of tumor cells. However, it remains undetermined whether 
DNAM-1 is involved in tumor immune surveillance in vivo. We addressed this question by 
using DNAM-1  –  defi  cient mice. DNAM-1  –  defi  cient cytotoxic T lymphocyte (CTL) and NK 
cells showed signifi  cantly less cytotoxic activity against DNAM-1 ligand-expressing tumors 
in vitro than wild-type (WT) cells. The methylcholanthrene (MCA)-induced fi  brosarcoma 
cell line Meth A expressed the DNAM-1 ligand CD155, and DNAM-1  –  defi  cient mice 
showed increased tumor development and mortality after transplantation of Meth A cells. 
Moreover, the DNAM-1  –  defi  cient mice developed signifi  cantly more DNAM-1 ligand-
expressing fi  brosarcoma and papilloma cells in response to the chemical carcinogens MCA 
and 7,12-dimethylbenz[a]anthracene (DMBA), respectively, than did WT mice. These 
results indicate that DNAM-1 plays an important role in immune surveillance of 
tumor development. 
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ing that the disruption of   Cd226   did not aff  ect lymphocyte 
diff  erentiation. We then examined the expression of DNAM-1 
ligands CD155 and CD112 in mouse tumor cell lines EL-4 
(H-2  b  ), RL male-1 (H-2  d  ), and BW5147 (H-2  k  ). These cell 
lines expressed comparable amounts of CD155 (  Fig. 1 A  ).   In 
contrast, CD112 was expressed on RMA transfectant expressing 
CD112 (RMA-CD112) but was barely detected on the other 
tumor cells (  Fig. 1 A  ). We next generated CTL by coculture 
of spleen cells from WT and DNAM-1  –  defi  cient BALB/c 
mice (H-2  d  ) with the RMA cell line (H-2  b  ) and then purifi  ed 
CD8  +   T cells by sorting. Because RMA cells did not express 
DNAM-1 ligands (  Fig. 1 A  ) and the population of CD8  +   
T cells after the culture was comparable between WT and 
KO spleen cells (not depicted), DNAM-1 defi  ciency did not 
aff  ect the induction of DNAM-1  –  defi  cient CTL cells. The 
purifi  ed WT and DNAM-1  –  defi  cient CD8  +   T cells specifi  -
cally killed EL-4 tumor cells as well as RMA transfectant 
expressing CD115 (RMA-CD155), but not RL male-1 or 
BW5147 (H-2  k  ) target cells, suggesting that both CTL were 
H-2  b   specifi  c (  Fig. 1 B  ). However, DNAM-1  –  defi  cient CTL 
were signifi  cantly less cytotoxic to RMA-CD155 and EL-4 
than were the WT CTL cells (  Fig. 1 B  ). 
  We also examined the cytotoxicity of DNAM-1  –  defi  -
cient NK cells. These cells showed no defect in cytolysis of 
Yac-1 tumor cells (Fig. S3, available at http://www.jem.org/
cgi/content/full/jem.20081611/DC1), which substantially 
express NKG2D ligands (  21  ) but not DNAM-1 ligands. 
nonhematopoietic and hematopoietic, including colorectal 
carcinomas (  15, 16  ), gastric cancers (  16  ), ovarian cancers (  17  ), 
neuroblastomas (  18  ), myeloid leukemias (  19  ), and multiple 
myeloma (  20  ), suggesting that DNAM-1 ligand expression 
might be induced by tumorigenesis and, thus, stimulates 
CTL and NK cells. However, it remains uncertain whether 
DNAM-1 is involved in immune surveillance of tumors in 
vivo. We therefore generated KO mice lacking the   Cd226   
(  DNAM-1  ) gene and investigated the in vivo role of DNAM-
1 in tumor immunity. 
    RESULTS AND DISCUSSION   
  Mouse DNAM-1 mediates cytotoxic activity of CTL 
and NK cells 
  Previous studies demonstrated that the addition of human 
DNAM-1  –  neutralizing antibodies to in vitro cytotoxicity as-
says inhibited CTL or NK cell  –  mediated lysis of several tumor 
cell lines expressing DNAM-1 ligands (  5, 10, 11  ), suggesting 
that human DNAM-1 is involved in CTL and NK cell  –  me-
diated cytotoxicity. However, the role of DNAM-1 in cyto-
toxicity of mouse CTL and NK cells has not been investigated. 
To address this issue, we generated mice lacking the   Cd226   
(  DNAM-1  ) gene in the BALB/c background (  DNAM-1   KO 
mice; Fig. S1, available at http://www.jem.org/cgi/content/
full/jem.20081611/DC1). Naive DNAM-1  –  defi  cient mice 
showed a normal composition of lymphocyte populations in 
the spleen, BM, and LN (Fig. S2 and not depicted), suggest-
    Figure 1.         DNAM-1 is involved in NK cell  –   and CTL-mediated cytotoxicity against DNAM-1 ligand  –  expressing tumor cell lines.   (A) Tumor cell 
lines or transfectants indicated were stained with anti-CD155 or anti-CD112 mAbs and analyzed by fl  ow cytometry. (B and C) H-2  b  – specifi  c CD8  +   CTL 
(B) or DX5  +   NK (C) cells from WT or DNAM-1  –  defi  cient BALB/c mice (H-2  d  ) were cocultured with   51  Cr-labeled target cells indicated for 3 h. Culture super-
natants were harvested and   51  Cr releases were counted. (D) WT (  n   = 5) or DNAM-1  –  defi  cient (  n   = 5) mice were injected i.p. with a 1:1 mixture of CFSE-
labeled RMA-S and RMA-S  –  CD155. 12 h after injection, cells were harvested from the peritoneal cavities and analyzed for the ratio of RMA-S  –  CD155 to 
RMA-S cells by fl  ow cytometry. Data are representative of three independent experiments. Error bars show SD.     JEM VOL. 205, December 22, 2008  2961
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MCA into WT and DNAM-1  –  defi  cient mice. Although 
  CD155   and   CD112   messenger RNAs (mRNAs) were barely 
detected in naive derma, MCA-induced fi  brosarcoma cells 
expressed signifi  cant quantities of both in both groups of 
mice (  Fig. 3 B  ). Notably, although the fi  brosarcoma cells ex-
pressed comparable amounts of   CD112   mRNA in both groups, 
  CD155   mRNA expression was signifi  cantly higher in the 
DNAM-1  –  defi  cient mice (  Fig. 3 B  ). These results suggest 
that DNAM-1 recognition of CD155 on fi  brosarcoma cells 
was involved in tumor immune surveillance, which is consistent 
with the   “  immunoediting  ”   theory in which immune responses 
select for variant tumor cells which have lost or decreased 
expression of specifi  c molecules that are targeted by immune 
eff  ector cells (  22  ). In contrast to CD155, CD112 seemed not 
to be involved in immunoediting. This may be explained by 
our previous observations that the affi   nities of homotypic bind-
ing of CD112 were likely to be higher than those of CD112 
binding to DNAM-1 (  12  ). 
  Recent studies using genetically engineered animals have 
demonstrated that a variety of immune cells in both the innate 
and adaptive immune systems are involved in tumor immuno-
editing of MCA-induced fi  brosarcoma (  4  ). Mice lacking cellular 
components such as          T cells (  23  ),          T cells (  23, 24  ), NK 
However, they showed less cytotoxicity to RMA-S  –  CD155 
cells than did WT NK cells (  Fig. 1, A and C  ). These results 
together formally demonstrate that DNAM-1 is involved in 
both CTL and NK cell  –  mediated cytotoxicity. 
  DNAM-1  –  defi  cient mice showed impaired clearance 
of CD155-expressing tumor cells 
  We next investigated the role of DNAM-1 in tumor clear-
ance in vivo. WT or DNAM-1  –  defi  cient mice were injected 
i.p. with a 1:1 mixture of CFSE-labeled RMA-S and RMA-
S  –  CD155 cells. At 12 h, tumor cells were harvested from the 
peritoneal cavity and analyzed for the ratio of cell numbers by 
fl  ow cytometry. We recovered signifi  cantly fewer RMA-S  –
  CD155 cells than RMA-S cells from WT mice than from 
DNAM-1  –  defi  cient mice (  Fig. 1 D  ). Considering the short 
time interval, NK cells, rather than CTL, might be involved 
in the clearance of RMA-S  –  CD155 cells. These results sug-
gest that DNAM-1 plays an important role in the clearance 
of tumors expressing CD155 in vivo. 
  DNAM-1  –  defi  cient mice showed higher mortality 
after transplantation of Meth A cells 
  We previously demonstrated that although RMA tumor cells 
grew in syngeneic mice, RMA-CD155 or RMA-CD112 cells 
were rejected by CD8  +   T cells and NK cells, suggesting that 
DNAM-1 was involved in the rejection (  16  ). To provide formal 
evidence for the role of DNAM-1 in protecting against 
DNAM-1 ligand-expressing tumors in vivo, we transplanted 
Meth A tumors that expressed CD155, but not CD112, into 
WT and DNAM-1  –  defi  cient mice (  Fig. 2 A  ).   When inocu-
lated with 2   ×   10  5   cells, both groups of mice developed tumors 
by 3  –  4 wk after inoculation, and their survival and mortality 
did not diff  er (  Fig. 2 B  ). However, when inoculated with 
2   ×   10  4   cells, all DNAM-1  –  defi  cient mice developed tumors 
by 20 d after inoculation, but 6 out of 10 WT mice showed no 
evidence of tumor development and the mortality of WT mice 
was signifi  cantly lower (  Fig. 2 C  ). These results indicate that 
DNAM-1 was involved in the rejection of the Meth A tumors. 
  DNAM-1 defi  ciency enhanced the development 
of 3-methylcholanthrene (MCA)  –  induced fi  brosarcoma 
  Because Meth A is an MCA-induced fi  brosarcoma cell line, 
we examined whether DNAM-1 might also be involved in 
immune surveillance of fi  brosarcoma after MCA injection. 
WT and DNAM-1  –  defi  cient mice were injected s.c. with 25 
or 400   μ  g MCA. At 400   μ  g MCA, both groups of mice simi-
larly developed fi  brosarcoma by 30 d after injection (  Fig. 3 A  ) 
and showed no diff  erence in mortality.   In contrast, at 25   μ  g 
MCA, WT mice developed tumors more slowly and survived 
signifi  cantly longer than DNAM-1  –  defi  cient mice (  Fig. 3 A  ). 
These results suggest that DNAM-1 played an important role 
in immune surveillance of MCA-induced fi  brosarcoma. 
  To further assess the role of DNAM-1 in immune sur-
veillance of MCA-induced fi  brosarcoma, we used quantita-
tive RT-PCR to evaluate DNAM-1 ligand expression on 
fi  brosarcoma cells that were developed after injection of 25   μ  g 
    Figure 2.         DNAM-1 is involved in tumor rejection in vivo.   (A)  Meth 
A cells were stained with anti-CD155 or anti-CD112 mAbs and analyzed 
by fl  ow cytometry. (B and C) WT (B,   n   = 5; C,   n   = 10) or DNAM-1  –  defi  cient 
(B,   n   = 5; C,   n   = 10) mice were inoculated s.c. with 2   ×   10  4   (B) or 2   ×   10  5  
(C) Meth A on day 0. Tumor size in each mouse was measured three times 
a week. Survival data per group are shown. The experiments were per-
formed twice with similar results. One experiment is shown.     2962 ACCELERATED TUMOR GROWTH IN DNAM-1  –  DEFICIENT MICE   | Iguchi-Manaka et al. 
  DNAM-1 defi  ciency enhanced the development of 7,12-
dimethylbenz[a]anthracene (DMBA)  –  induced papilloma 
  To examine whether DNAM-1 is involved in immune sur-
veillance of tumors other than MCA-induced fi  brosarcoma, 
we treated WT and DNAM-1  –  defi  cient mice with DMBA, 
a chemical carcinogen that induces papillomas on the skin. 
One out of fi  ve mice in each group developed papillomas by 
80 d after treatment with 400   μ  g DMBA alone, without 
12-  O  -tetradecanoylphorbol 13-acetate (  Fig. 4  ).   The number 
of DNAM-1  –  defi  cient mice with papillomas increased by 
100 d and all DNAM-1  –  defi  cient mice developed papillomas 
by 150 d, yet only the one WT mouse developed papillomas 
(  Fig. 4  ). The mean number of papillomas in DNAM-1  –  defi  -
cient mice was signifi  cantly higher than in WT mice (  Fig. 4  ). 
To further assess the role of DNAM-1 in immune surveillance 
cells (  25, 26  ), or NK T cells (  25  –  27  ) developed higher rates 
of MCA-induced fi  brosarcoma. The development of fi  bro-
sarcoma induced by MCA was also enhanced in mice defi  -
cient in   TRAIL   (  28  ) or injected with a neutralizing antibody 
against TRAIL (  29  ), which is constitutively expressed on 
liver NK cells and might be involved in NK cell  –  mediated 
immunity to fi  brosarcoma development. However, activat-
ing receptors constitutively expressed on T cells and NK cells 
in the spleen have not yet been identifi  ed. In the present and 
previous studies, we showed that DNAM-1 was involved in 
CTL and NK cell  –  mediated tumor cytolysis in vitro (  Fig. 1  ) 
and in the rejection of transplanted tumor cell lines (  29  ), sug-
gesting that DNAM-1 was responsible for CTL and/or NK 
cell  –  mediated immune surveillance of fi  brosarcoma develop-
ment induced by MCA. 
    Figure 3.         DNAM-1 is involved in immune surveillance against MCA-induced fi  brosarcoma.   (A) WT (  n   = 10) or DNAM-1  –  defi  cient (  n   = 10) mice 
were injected s.c. with 400   μ  g or 25   μ  g MCA on day 0. Tumor size in each mouse was measured once a week. Tumor incidence and survival data for 10 
mice per group are shown. (B) When 25   μ  g MCA-induced fi  brosarcomas in seven WT or nine DNAM-1  –  defi  cient mice reached a size of 1 cm in diameter, 
fi  brosarcoma was resected from each mouse and subjected to quantitative RT-PCR for   CD155   and   CD112  . The skins resected from four naive mice were 
also subjected to quantitative RT-PCR. The data are the mean of triplicates. The experiments were performed twice with similar results. One experiment 
is shown.     JEM VOL. 205, December 22, 2008  2963
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plate for 5 d and then with purifi  ed CD8  +   T cells by using the IMAG sorting 
system (BD). DX5  +   cells were purifi  ed from the spleen by using magnetic 
activated cell sorting (MACS; Miltenyi Biotec) and cultured in the presence 
of 200 ng/ml IL-2 for 5 d. Purities of CD8  +   and DX5  +   cells were   >  95%, as 
determined by fl  ow cytometry. 
  Cytotoxicity assay.     Cytotoxicity assays were performed as described previ-
ously (  11  ). 
  Tumor clearance assay.     WT or DNAM-1  –  defi  cient mice were injected 
i.p. with a 1:1 mixture of CFSE-labeled RMA-S and RMA-S  –  CD155 cells 
(10  6   each). 12 h after injection, tumor cells were harvested from the perito-
neal cavities and analyzed by fl  ow cytometry. 
  Tumor growth assay and survival of mice.     Groups of 5 or 10 WT or 
DNAM-1  –  defi  cient male mice were injected s.c. in the back with trans-
plantable tumor cell lines, with 25 or 400   μ  g MCA (Sigma-Aldrich) dissolved 
in 0.1 ml maize oil, or were painted with 400   μ  g DMBA (Sigma-Aldrich) 
dissolved in 4 mM of acetone. Mice were examined once or three times a 
week for tumor size with a caliper square, as previously described (  16  ). 
  Quantitative RT-PCR.     Total RNA was extracted from fi  brosarcomas and 
naive derma with Isogen reagent (Nippon Gene). For RT, we used 2  –  5   μ  g 
of total RNA in a High-Capacity cDNA Reverse Transcription kit (Applied 
Biosystems) at a fi  nal volume of 20   μ  l. Real-time PCR analysis of   CD155   
and   CD112d   was performed with an ABI 7700 sequence detector (Applied 
Biosystems) with Platinum SYBR Green qPCR SuperMix-UDG (Invitro-
gen). The primers were as follows:   CD155   forward, 5    -CAACTGGTAT-
GTTGGCCTCA-3     and reverse, 5   -ATTGGTGACTTCGCACACAA-3    ; 
and   CD112d   forward, 5    -CTCTGTGGATCGAATGGTCA-3     and re-
verse, 5    -GGCAGCGATAATACCTCCAA-3    . The   GAPDH   level was 
measured as an internal control (upper primer, 5    -CTTCACCACCATG-
GAGAAGGC-3    ; and lower primer, 5    -GGCATGGACTGTGGTCAT-
GAG-3    ) to normalize the data. The thermal cycling conditions comprised 
an initial denaturation step at 95  °  C for 10 min, followed by 40 cycles at 
95  °  C for 15 s and 60  °  C for 1 min. Standard curves were generated by using 
serial dilutions of cDNA from Meth A cells for   CD155   and BaF-CD112d 
cells for   CD112d  . All values were determined in triplicate. 
  Statistics.     Statistical analyses were performed by using the unpaired Stu-
dent  ’  s   t   test. 
  Online supplemental material.     Fig. S1 shows the construct of DNAM-1 
targeting vector, genomic   Cd226   analyzed by RT-PCR, the expression of 
  Cd226   mRNA in the tail, and DNAM-1 protein on the spleen cells by 
staining with FITC-conjugated anti-CD8 and biotin-conjugated anti  –
  DNAM-1 (TX42), followed with PE-conjugated streptavidin in the indi-
cated mice. Fig. S2 shows the lymphocytes population in the thymus and 
spleen cells derived from WT (  n   = 5) and DNAM-1  –  defi  cient (  n   = 5) mice. 
Fig. S3 show the cytotoxicities of Yac-1 by WT and DNM-1  –  defi  cient NK 
cells, as analyzed by   51  Cr releases assay. Online supplemental material is avail-
able at http://www.jem.org/cgi/content/full/jem.20081611/DC1. 
  We thank Lewis Lanier (University of California, San Francisco) for critical reading 
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of DMBA-induced papillomas, we examined the expression 
of   CD155   and   CD112   mRNAs in the papillomas by quanti-
tative RT-PCR. We detected both in signifi  cant amounts in 
all eight papillomas developed in DNAM-1  –  defi  cient mice 
(unpublished data). We also detected both in two papillomas 
developed in the WT mouse, but we could not statistically 
compare the expressions between groups. Nonetheless, these 
results indicate that DNAM-1 plays an important role in im-
mune surveillance of DMBA-induced papilloma as well as 
that of MCA-induced fi  brosarcoma. 
  Emerging evidence suggests that DNAM-1 plays an im-
portant role in T cell  –   and NK cell  –  mediated immunity to a 
variety of tumors expressing DNAM-1 ligands (  15  –  20  ). This 
is the fi  rst study using DNAM-1  –  defi  cient mice to demon-
strate direct genetic evidence for a role of the DNAM-1 re-
ceptor in immune surveillance of chemical carcinogen-induced 
tumors. Future studies aimed at the clinical application of 
DNAM-1 as a potential molecular target for the treatment of 
cancer should be interesting. 
  MATERIALS AND METHODS 
  Generation of DNAM-1 KO mice.     To construct the DNAM-1 targeting 
vector, we replaced exon 2  –  3 of the   Cd226   (  DNAM-1  ) gene with a neomy-
cin-resistant gene cassette using the bacterial artifi  cial chromosome system 
(  30  ). BALB/c embryonic stem cells were electroporated with the linearized 
DNAM-1 targeting vector, and cells were selected for G418 antibiotic resis-
tance. Correctly targeted embryonic stem cell clones with normal karyotypes 
were injected into 3.5-d-old BALB/c blastocysts to create chimeric mice 
(  Cd226  +/       ).   Cd226  +/        mice were intercrossed to generate   cd226      /        mice. 
Homozygous mice were obtained at the expected Mendelian frequencies 
and developed normally.   Cd226      /        mice and control WT mice were bred 
under specifi  c pathogen-free conditions in the same room of our animal 
facility. All experiments were performed according to the guidelines of 
the animal ethics committee of the University of Tsukuba Animal Re-
search Center. 
  Cell lines and antibodies.     RMA and EL-4 (  31  ) were H-2  b+   T lymphoma 
cell lines. Meth A, RL male-1, A20, and SP2/0 were H-2  d+   fi  broblast, T 
cell, B cell, and myeloma cell lines, respectively. BW5147 was an H-2  k+   T 
lymphoma cell line. Anti-CD8 and -DX5 monoclonal antibodies were pur-
chased from BD. Anti-DNAM-1 (TX42) (  16  ), anti-CD155 (TX56), and 
anti-CD112 (TX78) antibodies were generated in our laboratory. 
  Generation of CTL and NK cells.     We cocultured 5   ×   10  6   spleen cells 
with 10  6   RMA cells, pretreated with 100   μ  g/ml mitomycin C, in a 24-well 
    Figure 4.         DNAM-1 is involved in immune surveillance against 
DMBA-induced papilloma.   WT  ( n   = 5) or DNAM-1  –  defi  cient (  n   =  5) 
mice were treated with 400   μ  g DMBA on day 0. The number of papillomas 
developed in each mouse was observed twice a week. The mean number 
of papillomas and tumor incidence per group are shown. The experiments 
were performed twice with similar results. One experiment is shown.     2964 ACCELERATED TUMOR GROWTH IN DNAM-1  –  DEFICIENT MICE   | Iguchi-Manaka et al. 
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